Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 57 clinical trials
featured
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or

refractory follicular lymphoma
cancer
measurable disease
obinutuzumab
rituximab
  • 575 views
  • 24 Aug, 2021
  • 11 locations
featured
ACE-CL-007: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL

ACE-CL-007: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL

  • 981 views
  • 25 Mar, 2021
  • 3 locations
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).

  • 0 views
  • 06 Sep, 2021
  • 80 locations
ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

This study is a multicenter, open-label, uncontrolled, phase II trial aimed to establish the safety and tolerability of venetoclax, atezolizumab and obinutuzumab combination in Richter

  • 0 views
  • 22 Sep, 2021
  • 20 locations
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199) With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab

chemoimmunotherapy
venetoclax
rituximab
fludarabine
cyclophosphamide
  • 342 views
  • 20 Sep, 2021
  • 246 locations
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic

leukemia
obinutuzumab
platelet count
gilbert's syndrome
chronic lymphocytic leukemia
  • 0 views
  • 20 Jul, 2021
  • 14 locations
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by measuring

  • 1 views
  • 30 Mar, 2021
  • 1 location
A Dose Finding and Safety Study of CC-220 Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R

lymphoma
measurable disease
monoclonal antibodies
rituximab
  • 0 views
  • 19 Jul, 2021
  • 20 locations
Obinutuzumab in Marginal Zone Lymphoma

. The type II anti-CD20 antibody Obinutuzumab (OBINUTUZUMAB) has demonstrated remarkable activity in follicular lymphoma and superiority to Rituximab in combination with chemotherapy in treatment nave

refractory follicular lymphoma
cancer
measurable disease
b-cell lymphoma
corticosteroids
  • 25 views
  • 02 Feb, 2021
  • 24 locations
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

This is a phase II single-arm, open-label, multicenter study evaluating the efficacy and safety of the combination of induction chemoimmunotherapy with bendamustine and obinutuzumab (BO

cancer
measurable disease
renal function tests
mantle cell lymphoma
rituximab
  • 82 views
  • 14 Apr, 2021
  • 1 location